Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Yunpeng Liu
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06666166CT.gov SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT04446091CT.gov A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) | — | Unknown | — | — | — |
NCT03228043CT.gov Apatinib for Resectable Colorectal Cancer | — | Withdrawn | — | — | — |
NCT03193814CT.gov Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT04073615CT.gov A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) | — | Terminated | — | — | — |
NCT04067986CT.gov Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | — | Unknown | — | — | — |
NCT03377842CT.gov Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03397199CT.gov Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03403452CT.gov Apatinib in the Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03344614CT.gov A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
Show 3 more trialsShow fewer
NCT03210064CT.gov Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients | — | Unknown | — | — | — |
NCT03132025CT.gov Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT01531777CT.gov Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | Yunpeng Liu | P2 | B · 56 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivoceranib in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-colorectal-cancer-39625
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →